

**The Role of Adding Metformin to Insulin  
Therapy in Insulin-Resistant Diabetic  
Pregnant Women  
A Randomized Controlled Trial**

Submitted for Partial Fulfillment of Master Degree  
in Obstetrics and Gynecology

*By*

**Mohammed Anwar Haroun Bakhat**

M.B.B.Ch – Ain Shams University – 2007

*Under Supervision of*

**Prof. Salah Taha Fayed**

Professor of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Ahmed Hamdy Naguib**

Assistant Professor of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Adel Shafik Salah El-Din**

Lecturer of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2012**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَأَنْزَلَ اللَّهُ  
عَلَيْكَ الْكِتَابَ  
وَالْحِكْمَةَ  
وَعَلَّمَكَ مَا لَمْ  
تَكُنْ تَعْلَمُ وَكَانَ  
فَضْلُ اللَّهِ عَلَيْكَ  
عَظِيمًا

صدق الله العظيم

سورة النساء آية (١١٣)



*Before all, Thanks to GOD.*

I would like to express my profound gratitude to **Professor/ Salah Taha Fayed** Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his valuable advises and support all through the whole work and for dedicating much of his precious time to accomplish this work.

I am also grateful to **Dr. Ahmed Hamdy Naguib**, Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his continuous encouragement and supervision and kind care.

Last but not least I would like to express my thanks and gratitude to **Dr. Adel Shafik Salah EL-Din** Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his continuous encouragement and supervision and kind care.

I would like to thank **Dr/ Moustafa Ibrahim Ibrahim**, Assistant Prof. of Obstetrics and Gynecology for his scientific contrirubtion & for his valuable opinions during this study.

**Mohammed Anwar Haroun – 2012**

# LIST OF CONTENTS

Title	Page No.
List of Abbreviations .....	i
List of Tables .....	ii
List of Figures.....	iv
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
- Gestational Diabetes Mellitus .....	5
- Insulin Resistance .....	30
- Metformin in Pregnancy.....	43
Patients and Methods .....	58
Results .....	65
Discussion.....	89
Summary.....	102
Conclusion and recommendations .....	107
References.....	108
Arabic Summary .....	—

---

## List of Abbreviations

---

<b>AACE</b>	: American Association of Clinical Endocrinologists
<b>ADA</b>	: American Diabetes Association
<b>ADA</b>	: American Diabetes Association
<b>AMP</b>	: Activating adenosine monophosphate
<b>BMI</b>	: Body Mass Index
<b>CHD</b>	: Coronary heart disease
<b>DM</b>	: Diabetes mellitus
<b>FPD</b>	: Fasting plasma glucose
<b>GDM</b>	: Gestational diabetes mellitus
<b>HELLP</b>	: Hemolysis, elevated liver enzymes, and low platelet count
<b>IADPSG</b>	: Diabetes and Pregnancy Study Groups
<b>IDDM</b>	: Insulin-dependent diabetes mellitus
<b>IDF</b>	: International Diabetes Foundation
<b>IFG</b>	: Impaired fasting glucose
<b>IQR</b>	: Interquartile range
<b>MiG</b>	: Metformin in Gestational Diabetes Mellitus
<b>MODY</b>	: Maturity Onset diabetes of the Young
<b>NAFLD</b>	: Non-alcoholic Fatty Liver Disease
<b>NDDG</b>	: National Diabetes Data Group
<b>NIDDM</b>	: Noninsulin-dependent diabetes mellitus
<b>OGTT</b>	: Oral glucose tolerance test
<b>OGTT</b>	: Oral glucose tolerance test
<b>PCOS</b>	: Polycystic ovarian syndrome
<b>PCOS</b>	: Polycystic ovary syndrome
<b>PDM</b>	: Pre-existing diabetes mellitus
<b>RDS</b>	: Respiratory distress syndrome
<b>SD</b>	: Standard deviation

## **List of Tables *(of Review)***

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Etiological classification of diabetes mellitus .....	10
<b>Table (2):</b>	Classification of DM complicating pregnancy .....	11
<b>Table (3):</b>	Current screening and diagnostic strategies of GDM .....	14
<b>Table (4):</b>	Tests for gestational diabetes .....	15
<b>Table (5):</b>	Diagnostic criteria for GDM .....	18
<b>Table (6):</b>	Perinatal Morbidity in Diabetic Pregnancy .....	23
<b>Table (7):</b>	Definition of metabolic syndrome.....	37

## **List of Tables *(of Results)***

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Demographic data of included women.....	66
<b>Table (2):</b>	Type and duration of diabetes mellitus in included women.....	68
<b>Table (3):</b>	Initial Insulin dose in included women .....	69
<b>Table (4):</b>	Difference between groups regarding demographic data.....	70
<b>Table (5):</b>	Difference between groups regarding type and duration of DM with pregnancy .....	72
<b>Table (6):</b>	Difference between groups regarding initial Insulin dose .....	73
<b>Table (7):</b>	Daily dose of metformin and glycemic response in women of group I [Metformin Group].....	75
<b>Table (8):</b>	Insulin dose in women of group II [Control Group].....	77
<b>Table (9):</b>	Difference between groups regarding glycemic control .....	78
<b>Table (10):</b>	Association between Glycemic Control and Obesity among Women of Group I [Metformin Group].....	79
<b>Table (11):</b>	Difference between groups regarding mode of delivery.....	80
<b>Table (12):</b>	Difference between groups regarding gestational age at delivery, birth weight, 1-min and 5-min Apgar Scores.....	83
<b>Table (13):</b>	Difference between groups regarding neonatal complications .....	86

## List of Figures (*of Review*)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Effect of insulin on glucose uptake and metabolism.....	6



## **List of Figures (*of Results*)**

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	Bar-Chart showing age distribution in included women.....	67
<b>Figure (2):</b>	Bar-Chart showing distribution of gestational age at recruitment in included women .....	67
<b>Figure (3):</b>	Pie-Chart showing type of diabetes mellitus in included women.....	68
<b>Figure (4):</b>	Curve showing initial insulin dose in included women.....	69
<b>Figure (5):</b>	Box-Plot Chart showing difference between groups regarding age .....	71
<b>Figure (6):</b>	Box-Plot chart showing difference between groups regarding gestational age at recruitment.....	71
<b>Figure (7):</b>	Box-Plot chart showing difference between groups regarding BMI .....	72
<b>Figure (8):</b>	Box-Plot Chart showing difference between groups regarding type of DM with pregnancy.....	73
<b>Figure (9):</b>	Box-Plot showing difference between groups regarding initial insulin dose .....	74
<b>Figure (10):</b>	Pie-Chart showing daily dose of metformin in women of group I [Metformin Group].....	76

<b>Figure (11):</b>	Pie-Chart showing glycemic response in women of group I [Metformin Group] .....	76
<b>Figure (12):</b>	Bar-Chart showing difference between groups regarding glycemic control.....	78
<b>Figure (13):</b>	Bar-Chart showing Association between Glycemic Control and Obesity among Women of Group I [Metformin Group] .....	79
<b>Figure (14):</b>	Pie-Chart showing difference between groups regarding mode of delivery .....	81
<b>Figure (15):</b>	Bar-Chart showing difference between groups regarding indications for cesarean delivery .....	81
<b>Figure (16):</b>	Box-Plot chart showing difference between groups regarding birth weight .....	84
<b>Figure (17):</b>	Bar-Chart showing difference between groups regarding macrosomia .....	84
<b>Figure (18):</b>	Pie-Chart showing difference between groups regarding neonatal hypoglycemia.....	87
<b>Figure (19):</b>	Bar-Chart showing difference between groups regarding NICU admission.....	87
<b>Figure (20):</b>	Bar-Chart showing difference between groups regarding adverse perinatal outcome .....	88

## Introduction

The proportion of pregnant women with gestational and pregestational diabetes mellitus (DM) is increasing, mainly from an increase in type 2 DM (*Hedley et al., 2004; Metzger et al., 2007*). Obesity, low level of physical activity, and, possibly, the exposure to diabetes *in utero* are major contributors to the increase in type 2 diabetes (*Butte, 2000*).

Insulin has been the drug of choice for treating DM with pregnancy, because of its safety in pregnancy, lack of significant transplacental passage and long history of use (*Pridjian and Benjamin, 2010*).

Pregnant diabetic women not uncommonly show poor glycemic control that necessitates hospital admission during their antenatal follow-ups. Of them a significant proportion, particularly those who are obese with long-standing pregestational diabetes mellitus, show some insulin resistance, that requires further increase in insulin dose over variable periods of hospital stay. Prolonged hospital stay is known to be associated with several adverse events including a higher risk of nosocomial chest and urinary tract infections, venous thromboembolism, in addition to the high cost. Prolonged hospitalization, on its own, may even worsen glycemic control (*ACOG, 2001*). Moreover, insulin, in high doses, is associated with weight gain and bouts of hypoglycemia (*Rowan et al., 2008*).

In the 21<sup>st</sup> century, oral hypoglycemic agents have been included in the armamentarium of treatment modalities for gestational diabetes mellitus (GDM). Earlier concerns with use of these agents in pregnancy were the unknown risk of teratogenicity and neonatal hypoglycemia caused by transplacental passage (*Pridjian and Benjamin, 2010*). Several randomized controlled trials have been conducted on the use of different oral hypoglycemic drugs as a substitute to insulin in women with GDM; the results of all of which were promising. Glycemic control and neonatal outcome in women who received oral hypoglycemic agents, namely the sulfonylurea glyburide and the biguanide metformin, were comparable to those who received insulin (*Rowan et al., 2008*).

Metformin is a biguanide that improves insulin sensitivity, probably by activating adenosine monophosphate (AMP) kinase. In contrast to insulin, metformin is not associated with weight gain or hypoglycemia. Reported outcomes of its use during pregnancy have been favorable (*Shao et al., 2000; Kirwan et al., 2002*). The safety of use of metformin during pregnancy are mainly derived from reports of women with polycystic ovarian syndrome (PCOS) who got pregnant while using metformin (*Pridjian and Benjamin, 2010*). Metformin is now categorized by the FDA regarding its safety for use in pregnancy as category B (*Pridjian and Benjamin, 2010*). Metformin has been studied in treatment of GDM in two randomized controlled trials. Rowan et al. randomized a number of women with GDM to receive either

metformin or insulin. Of the 363 women who received insulin, 336 (92.6%) continued on metformin till delivery, but 168 (46.3%) required supplemental insulin to achieve euglycemia. Neonatal outcomes were similar in both groups, and women preferred to use metformin even if insulin was added (**Rowan et al., 2008**). In another randomized controlled trial, Moore et al. compared the use of metformin to glyburide for treatment of GDM. Euglycemia was achieved in 65.3% of women who received metformin, while 34.7% needed supplemental insulin (**Moore et al., 2010**).

To our best knowledge, oral hypoglycemic agents have not been suggested as alternative to insulin in women with pregestational DM. The current recommendation is to switch women with type 2 DM, who have been maintained on metformin and get pregnant, to insulin even if unexpected pregnancy occurs (**Pridjian and Benjamin, 2010**). The promising results of the few randomized trials on the use of metformin as an alternative to insulin in women with GDM, encourages us to try it, not as an alternative to insulin, but as an ‘adjuvant’ in women with DM with pregnancy who show insulin resistance.

## **Aim of the Work**

The aim of the present study is to assess the impact of adding oral metformin to insulin therapy in pregnant women with resistant diabetes mellitus.

## **Gestational Diabetes Mellitus**

### **Definition**

*G*estational diabetes mellitus (GDM), a common medical complication of pregnancy, is defined as “any degree of glucose intolerance with onset or first recognition during pregnancy”. The definition has applied whether or not insulin is used for treatment or hyperglycemia persists after pregnancy. The possibility that unrecognized glucose intolerance antedated the pregnancy is not excluded (*Metzger et al., 1998; ADA, 2009*).

However, in 2010, the International Association of Diabetes and Pregnancy Study Groups (IADPSG), an international consensus group with representatives from multiple obstetrical and diabetes organizations, including the American Diabetes Association (ADA), recommended that women found to have diabetes at their initial prenatal visit, using standard criteria, receive a diagnosis of overt, rather than gestational diabetes (*ADA, 2010*).

The rationale for this change is that more and more women have personal risk factors, such as obesity, for diabetes, and are therefore being screened early in pregnancy. Women diagnosed in the first trimester likely had pre-existing diabetes unrecognized prior to pregnancy rather than impaired glucose tolerance due to pregnancy-related hormonal changes, which are most pronounced later in gestation.